Spero Therapeutics, Inc.
corporate_fare Company Profile
Spero Therapeutics, Inc. (NASDAQ:SPRO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for SPRO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for SPRO spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Spero Q3 Loss Widens to $44.3M on $35M SP001 Upfront; Cash of $107.9M Funds Runway Into 2H 2029
- Spero Posts $44.3M Q3 Loss, Far Exceeding Prior Quarter's $9.6M
- Spero's Q2 Loss Widens, but $105M Royalty Financing Extends Runway to 2029
- Spero Q2 Loss Widens to $9.6M as Revenue Drops to Zero
- Spero In-Licenses Phase 2-Ready Anti-CD40L Antibody SP001 and Secures $105M Non-Dilutive Royalty Financing, Extending Cash Runway into 2H 2029
Financial Snapshot
Short Interest & Short Volume
2.23 days to coverFINRA reported short interest of 787,025 shares in SPRO as of the October 30, 2026 settlement, a 6.4% decrease from the prior period — about 2.2 days to cover at its recent average daily volume. On November 20, 2026, 31.8% of SPRO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for SPRO, detected from its recent SEC filings.
$300M Universal Shelf Registered · $100M ATM Program with Jefferies
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →